Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Soltego Inc. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution effort is localized within 1 distinct art unit and assigned to 1 distinct examiner, which indicates a very specific technical focus for the company's current filings. The lack of broader distribution across different examiners or units suggests that the company is prioritizing a single biotechnological or pharmaceutical innovation at this time.
The busiest examiner for the portfolio is LADD, CAROLYN LOUISE, who is responsible for the 1 busiest examiner pending office action currently active. As the sole examiner assigned to the company's workload, their individual interpretation of patent law and technical claims will be the primary driver of the portfolio's success. The reliance on 1 distinct examiner means that the applicant's near-term outcomes are tied directly to the specific examination patterns of this one official.
Because the portfolio consists of only 1 pending office action, the administrative complexity of managing these filings is minimal. The focus on 1 distinct art unit allows for a targeted prosecution approach within the Biotechnology & Pharmaceuticals sector. Future filings would be necessary to expand the company's footprint and move beyond this single point of contact within the patent office to ensure long-term growth.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18027556 | SIK INHIBITORS AND METHODS OF USE THEREOF | LADD, CAROLYN LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18027556 | SIK INHIBITORS AND METHODS OF USE THEREOF | LADD, CAROLYN LOUISE | 1622 | §103 | Final Rejection | — | Pending | Mar 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSoltego Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Carolyn Louise Ladd has the most, with 1 of Soltego Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
